

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/GB05/000541

International filing date: 15 February 2005 (15.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB

Number: 0403628.1

Filing date: 18 February 2004 (18.02.2004)

Date of receipt at the International Bureau: 24 June 2005 (24.06.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ


GB/05/541

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed      Andrew Jersey  
Dated    15 June 2005





1777

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

 Cardiff Road  
 Newport  
 South Wales  
 NP10 8QQ

1. Your reference

GWS/CMS/25943

 19FEB04 EB74408-1 D02000  
 P01/7700 0.00-0403628.1 CHEQUE

0403628.1

2. Patent application number

(The Patent Office will fill in this part)

 3. Full name, address and postcode of the or of  
 each applicant (underline all surnames)

08811440001

Patents ADP number (if you know it)

 If the applicant is a corporate body, give the  
 country/state of its incorporation

 ARROW NO. 7 LIMITED  
 Arrow Group Ltd  
 4th Floor  
 7 Cavendish Square  
 London  
 W1G 0PE  
 United Kingdom

 AR  
 11/77  
 31.5.05

4. Title of the invention

Compression-coated tablets and the manufacture thereof

5. Name of your agent (if you have one)

 "Address for service" in the United Kingdom  
 to which all correspondence should be sent  
 (including the postcode)

 MATHYS & SQUIRE  
 100 Gray's Inn Road  
 London WC1X 8AL  
 United Kingdom

Patents ADP number (if you know it)

1081001✓

 6. If you are declaring priority from one or more  
 earlier patent applications, give the country  
 and the date of filing of the or of each of these  
 earlier applications and (if you know it) the or  
 each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)
 7. If this application is divided or otherwise  
 derived from an earlier UK application;  
 give the number and the filing date of  
 the earlier application

Number of earlier application

Date of filing  
(day / month / year)
 8. Is a statement of inventorship and of right  
 to grant of a patent required in support of  
 this request? (Answer 'Yes' if:

YES

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d)

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description	19
Claim(s)	4
Abstract	1 ✓
Drawing(s)	4 ✗

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)Request for preliminary examination and search (*Patents Form 9/77*)

1 ✓

Request for substantive examination  
(*Patents Form 10/77*)Any other documents  
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

*MATHYS & SQUIRE*

Date

16 February 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

George Schlich - 020 7830 0000

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.



1777

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

 Cardiff Road  
 Newport  
 South Wales  
 NP10 8QQ

1. Your reference

GWS/CMS/25943

19FEB04 EB74408-1 D02000  
P01/7700 0.00-0403628.1 CHEQUE

2. Patent application number

0403628.1

(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

08811440001

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

 ARROW NO. 7 LIMITED  
Arrow Group Ltd  
 4th Floor  
 7 Cavendish Square  
 London  
 W1G 0PE  
 United Kingdom

 AR  
 16/77  
 31.5.05

4. Title of the invention

Compression-coated tablets and the manufacture thereof

5. Name of your agent (*if you have one*)
 "Address for service" in the United Kingdom  
 to which all correspondence should be sent  
*(including the postcode)*

 MATHYS & SQUIRE  
 100 Gray's Inn Road  
 London WC1X 8AL  
 United Kingdom
Patents ADP number (*if you know it*)

1081001✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
*(if you know it)*Date of filing  
*(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
*(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d)

YES

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description	19
Claim(s)	4
Abstract	1 ✓
Drawing(s)	4 ✗

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)Request for preliminary examination and search (*Patents Form 9/77*)

1 ✓

Request for substantive examination  
(*Patents Form 10/77*)Any other documents  
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

*MATHYS & SQUIRE*

Date

MATHYS &amp; SQUIRE

16 February 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

George Schlich - 020 7830 0000

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

**COMPRESSION-COATED TABLETS  
AND THE MANUFACTURE THEREOF****Technical Field**

5

The present invention relates to the field of tablet formulation. The invention is of application to active agents generally, but in particular, the invention relates to sumatriptan-containing tablets for the treatment of migraine, and methods of producing such tablets.

10

**Background**

- Migraine is a common and debilitating condition that affects up to 10-15% of the population. The classical pattern of events in a migraine attack consists of an initial visual disturbance, followed, about 30 minutes later, by a severe throbbing headache, starting unilaterally, often with photophobia, nausea, vomiting and prostration.
- Whilst the pathophysiology of migraine is not well understood, it is widely accepted that there is some relation between migraine and changes in cerebral blood flow. There is also strong evidence to implicate the neurotransmitter 5-hydroxytryptamine (5-HT), and many of the drugs that are effective in treating migraine are 5-HT receptor agonists or antagonists. One such drug is sumatriptan, an agonist of 5-HT<sub>1D</sub> receptors, which receptors are predominantly expressed in cerebral blood vessels.

Many anti-migraine drugs have, until recently, been administered via injection, ie. as a liquid preparation. This has the advantage that the drugs are rapidly released into the systemic circulation and delivered to their sites of action - they can therefore

act rapidly to relieve the symptoms of a migraine attack.

There are also, however, well-known disadvantages associated with the administration of drugs via injection; for example, the comparative difficulty in 5 administration compared to a drug in tablet form, patient non-compliance, and safety issues relating to needles. Significant efforts have thus been made to develop oral tablets.

An oral tablet preparation of an anti-migraine drug must, as discussed above, rapidly 10 release the drug into the stomach so that it can be absorbed into the systemic circulation and delivered to its site of action. An oral tablet preparation must also mask the unpleasant taste of the anti-migraine drug. Patients suffering a migraine attack are likely to experience nausea and vomiting - and are thus more averse than usual to the unpleasant taste of the drugs.

15

One solution to this taste-masking problem has been to coat oral tablet preparations with a layer of polymers, a process known as 'film coating'. Film coating masks the taste of the drug when the tablet is placed into the mouth, but dissolves rapidly in the stomach so as to allow rapid release and absorption of the drug. Film-coated 20 sumatriptan tablets are described in WO 92/15295, US 6368627, US 6020001 and US 5863559.

Film coating is well established as a method of coating tablets and is used widely in the pharmaceutical industry. In brief, core tablets are compressed on a standard 25 tablet press and transferred into a pan (typically a side vented coating pan). A mixture of, *inter alia*, polymers, colorants, opacifiers, and plasticizers is mixed with water/solvents to create a coating dispersion. Warm air is passed through the bed of tablets while the coating dispersion is sprayed onto the tablets, forming the so-called "film".

30

The process of film coating, however, requires expensive equipment for application

of the layer of polymers, and also requires a drying step to fix the polymers onto the tablet . In addition, the process of film-coating (eg. by heating/moisture exposure) can stress the chemical composition/stability of the tablet and its active ingredient(s). Film coated tablets also require the use of a greater number of excipients, which can leave the active prone to reaction and degradation.

Alternative methods of masking the taste of unpleasant-tasting drugs in oral tablet preparations include the use of a mantle, free of drug, compressed around a core tablet containing the drug. Mantles of this type have been used to produce delayed release tablets (where the mantle is comprised of slowly dissolving material, delaying the release of the active), and sustained release tablets (the mantle acting as a semi-permanent barrier to the active contained in the core which must pass through the insoluble or partially soluble mantle). Other uses include a burst effect tablet, where an immediately-releasing mantle is coated over a sustained release core.

A disadvantage of these compression-coated tablets is the relatively large weight of the mantle, typically in excess of two times that of the core - hence, for a given core, adding a mantle will at least triple the size of the tablet.

It is desirable to develop a method of formulating these unpleasant tasting drugs, e.g. anti-migraine drugs, in an oral tablet preparation, said preparation having both taste-masking and rapid-release characteristics.

Accordingly, it is an object of the invention to provide an oral tablet preparation wherein the unpleasant taste of a drug is masked.

A further object is to provide an oral tablet preparation which allows rapid drug release.

It is a specific object of the invention to provide an oral tablet preparation of

sumatriptan, wherein the unpleasant taste of sumatriptan is masked. A further specific object of the invention is to provide an oral tablet preparation of sumatriptan, wherein the unpleasant taste of sumatriptan is masked, and wherein release of sumatriptan from the tablet core is rapid.

5

### **Summary of Invention**

Accordingly, the present invention provides a tablet, comprising:-

- 10 (i) a core containing sumatriptan, and  
(ii) a mantle, free of sumatriptan.

Tablets of the invention provide for rapid release of sumatriptan (reference to which indicates sumatriptan or a pharmaceutically acceptable salt or ester thereof) whilst

- 15 the mantle of the tablet masks its unpleasant taste. Preferably, the weight ratio of mantle:core is equal to or less than 1.8:1, and more preferably the weight ratio of mantle:core is equal to or less than 1.5:1 and especially equal to or less than 1.3:1.  
The amount of sumatriptan is present in an amount effective to counter migraine, and suitably the core contains from 10-200 mg of sumatriptan.

20

More generally, the invention relates to use of compression-coating technology to mask an unpleasant taste in a tablet where the active needs to be rapidly released. Hence, in a further embodiment of the invention there is provided a tablet, comprising:-

- 25 (i) a core containing an active agent, and  
(ii) a mantle, free of active agent.

- 30 Preferably, the weight ratio of mantle:core is equal to or less than 1.8:1, and more preferably the weight ratio of mantle:core is equal to or less than 1.5:1 and especially equal to or less than 1.3:1.

The invention additionally provides a method of producing a tablet, comprising the steps of:-

- 5           a) forming a core by:-  
               (i) placing a first amount of powder/granule in a press,  
               (ii) compressing said first amount of powder/granule to obtain a core, and  
               b) pressing a second amount of powder/granule around said core,  
               thereby forming a mantle and obtaining the final tablet.

10 **Brief Description of the Figures**

Figure 1 shows the tablet press procedure used in the production of (i) a known compressed tablet and (ii) a compression-coated tablet of the invention.

- 15 Figure 2 shows the dissolution profile of a tablet of the invention containing 25mg of sumatriptan, as compared to a commercially-available Imitrex tablet containing 25mg of sumatriptan.

20 Figure 3 shows the dissolution profile of a tablet of the invention containing 50mg of sumatriptan, as compared to a commercially-available Imitrex tablet containing 50mg of sumatriptan.

- 25 Figure 4 shows the dissolution profile of a tablet of the invention containing 100mg of sumatriptan, as compared to a commercially-available Imitrex tablet containing 100mg of sumatriptan.

**Detailed Description of the Invention**

- 30 Tablets of the invention are suitably formulated such that both the core and the

mantle dissolve rapidly in the stomach. The dissolution can vary but a suitable dissolution profile is one in which at least 90% of the tablet is dissolved after 10, especially after 5, minutes, preferably 95% of the tablet is dissolved after 10, especially 5 minutes, as measured by the standard paddle method.

5

Generally, the core and the mantle disintegrate over substantially the same time period. The disintegration can be different however, and other tablets of the invention have a dissolution profile wherein the mantle is at least 95 % dissolved and the core is at least 90 % dissolved after 10, preferably after 5, minutes.

10

In preferred embodiments, the core of the tablet is usually comprised of one or more of the following components (referred to as the "core blend"):-

filler, binder, disintegrant, lubricant, active ingredient.

15

The filler can be any suitable filler that is pharmaceutically compatible with the active ingredient. Particular examples include, but are not limited to, Lactose, Calcium Phosphate, Calcium Sulfate, Compressible Sugar and derivatives thereof, Celluloses and derivatives thereof, Maltodextrin, and modified starches, or any combination thereof.

20

The binder can be any suitable binder that is pharmaceutically compatible with the active ingredient. Particular examples include, but are not limited to, Acacia, Carbomer, Carboxymethylcellulose Calcium (or Sodium), Cellulose Acetate

25 Pthalate, MCC, Dextrates, Ethylcellulose, Gelatin, Liquid Glucose, Povidone, Starch (dry or as a paste), Guar Gum, Hydroxypropyl cellulose, HPMC, Maltodextrin. Poloaxmer and PEG, or any combination thereof.

The disintegrant can be any suitable disintegrant that is pharmaceutically compatible  
30 with the active ingredient. Particular examples include, but are not limited to, Alginic Acid, Calcium Phosphate Tribasic, Carboxymethylcellulose Calcium (or Sodium),

MCC, Croscarmellose Sodium, Crospovidone, Docusate Sodium, Low substituted Hydroxypropyl Cellulose, magnesium aluminium Silicate, Polacrilan Potassium, Sodium Alginate, Sodium Bicarbonate, Sodium Starch Glycolate, Starch and Pregelatinized Starch, or any combination thereof.

- 5       The lubricant can be any suitable lubricant that is pharmaceutically compatible with the active ingredient. Particular examples include, but are not limited to, Calcium Stearate, Canola Oil, Hydrogenated Castor Oil, Colloidal Silicon Dioxide, Cottonseed Oil, Fumaric Acid, Glyceryl Monostearate, Glyceryl Palmitostearate,
- 10      Magnesium Stearate, Mineral Oil, Poloxamer, Polyethylene Glycol, Polyoxyethylene Stearate, Polyvinyl Alcohol, Sodium Benzoate, Sodium Chloride, Sodium Lauryl Sulfate, Sodium Stearyl Fumarate, Stearic Acid, Talc, Hydrogenated Vegetable Oil, Glyceryl Dibehanate and Zinc Stearate, or any combination thereof.
- 15      The active ingredient is generally any active ingredient or mixture of active ingredients, though the invention is particularly suitable for actives which have an unpleasant taste and which are desired to be released rapidly. In specific embodiments, described in more details in examples below, the active is an anti-migraine drug, including 5-HT receptor agonists or antagonists or any combination thereof. Preferably, the active ingredient is sumatriptan. More preferably, the active ingredient is sumatriptan succinate. The tablets of the invention can each contain between 10 and 200 mg of active ingredient (free base), preferably between 25 and 100mg, more preferably 25, 50 or 100 mg.
- 20      In preferred embodiments, the mantle is usually composed of one or more of the following components (referred to as the "mantle blend"):-
- 25                  filler, binder, disintegrant, lubricant.
- 30      These components can be any of those mentioned above, or any combination thereof.

It is further optional that the core and the mantle are composed of substantially the same materials, apart from the active, which is in the core.

- In addition, both the core and mantle blends may optionally comprise adsorbants  
5 and/or colorants. Any pharmaceutically acceptable colorant or adsorbant could be used.

The core and mantle blends are preferably prepared by dry blending (for ease of manufacture) but wet granulation or compaction granulation could be used.

10

In general, the components of the respective blends, except the lubricant, are blended together in a first blending step. More than one blending step may be required if colorant is to be added, so that the colorant is distributed uniformly within the blend. The lubricant is subsequently blended with the result of the first blending

15 step.

In a particular embodiment, the core comprises, by weight:-

20	active ingredient:	1-40%
	filler:	10-90%
	binder:	2-60%
	disintegrant:	1-60%
	lubricant:	0.1-10%
	adsorbants:	0-5%
25	colorants:	0-5%,

and the mantle comprises, by weight:-

30	filler:	10-90%
	binder:	2-60%
	disintegrant:	1-60%

lubricant: 0.1-10%  
adsorbants: 0-5%  
colorants: 0-5%.

5 In a preferred embodiment, the core tablet comprises:-

10 Sumatriptan Succinate  
Microcrystalline Cellulose  
Croscarmellose Sodium  
Purified Water  
Magnesium Stearate

15 and the mantle of the tablet comprises:-

20 Lactose  
Microcrystalline Cellulose  
Croscarmellose Sodium  
Iron Oxide Red  
Magnesium Stearate.

An advantage of specific tablets of the invention is that they act rapidly to relieve the  
25 symptoms of a migraine attack, as the active agent in the tablets is rapidly released  
into the stomach, so that it can be absorbed into the systemic circulation and  
delivered to its site of action. The tablets of the invention have additionally been  
shown to have improved dissolution profiles compared to commercially-available  
oral tablet preparations of sumatriptan, as evidenced in Example 4.

30

Tablets of the invention can be prepared by:-

(A) forming a core by:-

- (i) placing a first amount of powder/granule in a press,
  - (ii) compressing said first amount of powder/granule to obtain a core, and
- (B) forming a mantle around the core by:-
- 5 (i) placing a second amount of powder/granule in a press,
  - (ii) placing said core onto said second amount of powder/granule,
  - (iii) placing a third amount of powder/granule on top of the core and the second amount of powder/granule, and
  - (iv) compressing (iii) so as to obtain the final tablet.

10

The core compression in Step A is suitably carried out at a pressure of from 0.5-5 tons, resulting in a partially-compressed core. This core is sufficiently compressed to remain intact during subsequent processing steps, and prior to further compression in Step B.

15

The compression in Step B is generally carried out at a higher pressure, suitably carried out at a pressure of from 0.5-10 tons, to yield the final tablet.

In a method for making tablets of the invention, the tablets are formed using the  
20 process shown schematically in Fig 1. Specifically, the tablet is formed in two stages. First, a core is formed from a core blend containing active. Subsequently, a mantle blend, free of active, is compressed around this core to form the final tablet.

25 To form the core, a given amount of a first powder/granule (ie. the core blend, containing active) is compressed on a conventional tablet press. Preferably, the compression is carried out at a pressure of 0.5-5 tons, to form a partially-compressed core. This partial compression hold the components of the core together, but is not compressed to its final hardness/thickness.

30

To form the final tablet, a given amount of a second powder/granule (ie. the mantle blend, free of active) is placed in a press, onto which the core is placed. The core is then covered with an additional amount of a third powder (also mantle blend), and all components forming the tablet are then compressed to the final hardness and thickness. Preferably, the compression is carried out at a pressure of 0.5-10 tons.

- 5 The tablets of the invention may be formed by a process wherein both the core and mantle blends are placed onto the two sides of a single machine (e.g. a Manesty Dry-Cota tablet press). The core blend is again partially compressed (compressed, 10 but not to its final hardness/thickness, only sufficient to hold together until it is transferred) on the core side of the press and then transferred to the mantle side of the press where it is sandwiched in the mantle blend. This core/mantle blend is then compressed into the final, compression-coated tablet.
- 15 Preferably, the tablets of the invention have a friability index of less than 1%, more preferably less than 0.8%.

We have found that, following the invention, it is possible for the core of the tablet to be produced using approximately half the quantity of the excipients used in other 20 commercially-available sumatriptan tablets. Surprisingly, and despite the small quantity of excipients used, adequate disintegration/dissolution of the core is achieved.

Furthermore, we have also found that good mantle coverage can be achieved with 25 a low ratio (by weight) of mantle:core. For example, whereas a typical prior art weight ratio of mantle:core would be 2:1, a good mantle coverage is achieved in the invention with a ratio as low as approximately 1.15:1.

The invention is now described and illustrated in the following examples.

**Example 1**

- 5 The core tablet (Items 1-8) and mantle (Items 9-13) were formulated as shown in Table 1 below.

10

15

20

25

30

Item	Ingredient	mg/tab		
		25 mg	50 mg	100 mg
5	1 Sumatriptan Succinate	35.00	70.00	140.00
	2 Microcrystalline Cellulose	18.20	36.40	72.80
	3 Croscarmellose Sodium	2.80	5.60	11.20
	4 Purified Water	q.s.	q.s.	q.s.
	5 Purified Water	q.s.	q.s.	q.s.
10	<b>Add Drys</b>			
15	6 Microcrystalline Cellulose	10.5	21	42
	7 Croscarmellose Sodium	2.8	5.6	11.2
	8 Magnesium Stearate	0.7	1.4	2.8
	<b>Total Tablet Core Weight</b>	70	140	280
	<b>Mantle Blend</b>			
20	9 Lactose	41.75	83.5	167
	10 Microcrystalline Cellulose	35.75	71.5	143
	11 Croscarmellose Sodium	1.6	3.2	6.4
	12 Colorant **	0.1	0.2	0.4
	13 Magnesium Stearate	0.8	1.6	3.2
25	<b>Total Tablet Weight</b>	150	300	600

\*\* Optional colorant. If not used, replace with lactose.

**Table 1:- Formulation of core and mantle blends.**

30

In these particular formulations, Lactose acts as a filler, Microcrystalline Cellulose acts as a binder/disintegrant and filler, Croscarmellose Sodium acts as a disintegrant, and the Magnesium Stearate acts as a lubricant.

### Example 2

With reference to Table 1 of Example 1, tablets were manufactured as follows:-

- 5 Items 1-3 were transferred into a high shear mixer/granulator after being pre-screened. The powders were mixed for 2 minutes at settings of High Mix and High Chop. Items 4-5 were then used to granulate the material under the same settings. After a suitable granule was achieved, this was discharged into the bowl of a fluid bed dryer and the material dried at a temperature of 50° C to a Loss On Drying (LOD) reading of less than 2%.
- 10

The dried granule was milled through a screen to remove the oversized particles (a screen size of approximately 425-1400 microns can be used, preferably 600 microns).

15

The milled granule was transferred to an appropriately sized tumble blender, along with Items 6 & 7 (after pre-screening). These were blended for 10 minutes prior to addition of Item 8 (again pre-screened). Final blending was effected for 5 minutes. This completed the so-called "core blend".

20

Separately, Items 9-12 (pre-screened) were transferred into an appropriately sized tumble blender and blended for 10 minutes. If Item 12 (the optional colorant) is used, an intermediate blending step with one of the other ingredients, may be used to properly disperse the colorant into the blend. Pre-screened Item 13 was added to the blender and final mixing effected for 5 minutes. This completed the so-called "mantle blend."

The core and mantle blends were then placed onto the two sides of a Manesty Dry-Cota tablet press. The core blend was partially compressed (not to its final hardness/thickness, but sufficient to hold together until transferred) on the core side

of the press and then transferred to the mantle side of the press where it was sandwiched in a bed of the mantle blend. This core/mantle blend was then compressed into the final, compression-coated tablet. Other methods of compression coating can be used, e.g. by compressing core tablets on one machine  
5 and then transferring them to a separate machine for compression coating.

### **Example 3**

10 Tablets A, B and C, containing 25 mg, 50 mg, and 100 mg of sumatriptan respectively, were made in accordance with Example 1.

The dissolution profiles of tablets A-C were tested using the standard Paddle Method (see European Pharmacopoeia) and the results are shown in Tables 2-4.

15 These tables also provide comparative dissolution profiles of commercially-available sumatriptan tablets manufactured by GlaxoSmithKline (Imitrex).

		Time Points (Minutes)					
		Tablet	0	5	10	15	20
5	Tablet A 25 mg	1	0	97.9	98.1	98.0	97.9
		2	0.0	100.5	100.8	100.7	100.6
		3	0.0	99.1	99.7	99.6	99.4
		4	0.0	98.0	98.9	98.8	98.8
		5	0.0	97.8	99.4	98.8	98.7
		6	0.0	99.6	99.8	99.8	99.7
		7	0.0	100.4	100.9	100.8	100.8
		8	0.0	98.3	99.2	99.1	99.1
		9	0.0	99.8	100.4	100.4	100.5
		10	0.0	99.3	100.1	100.1	100.3
		11	0.0	97.6	98.5	98.5	98.6
		12	0.0	98.1	99.0	99.1	99.2
		Mean	0	99	100	100	100
10	Imitrex 25 mg	1	0.0	53.5	97.8	101.5	101.5
		2	0.0	67.1	101.2	101.9	102.0
		3	0.0	67.4	101.2	101.7	101.7
		4	0.0	58.1	98.1	102.1	102.2
		5	0.0	71.1	100.1	100.6	100.6
		6	0.0	76.2	99.9	99.7	99.6
		7	0.0	61.3	98.6	100.1	100.1
		8	0.0	65.6	98.8	99.4	99.6
		9	0.0	61.2	97.3	97.9	97.9
		10	0.0	60.6	100.9	101.6	101.6
		11	0.0	78.8	99.3	99.6	99.6
		12	0.0	63.2	100.7	101.3	101.4
		Mean	0	65	100	101	101

20

**Table 2: Comparison of Dissolution Profiles by UV in 0.1 N HCl**  
**Tablet A (25 mg) vs Imitrex Tablets 25 mg (GSK)**

		Time Points (Minutes)				
		0	5	10	15	20
Tablet B 50 mg	1	0.0	99.8	99.8	99.6	99.3
	2	0.0	101.1	100.7	100.2	100.0
	3	0.0	99.2	100.0	99.7	99.6
	4	0.0	99.9	100.7	100.6	100.5
	5	0.0	91.7	99.6	99.6	99.5
	6	0.0	99.0	99.9	99.7	99.7
	7	0.0	99.4	99.5	99.5	99.1
	8	0.0	100.5	100.2	100.1	99.9
	9	0.0	99.0	99.7	99.6	99.4
	10	0.0	99.6	100.6	100.5	100.3
	11	0.0	91.4	99.5	99.6	99.3
	12	0.0	98.5	99.8	99.5	99.6
	Mean	0	98	100	100	100
Imitrex 50 mg	1	0.0	90.2	99.5	99.7	99.8
	2	0.0	85.9	99.2	99.4	99.5
	3	0.0	86.9	99.7	99.9	100.0
	4	0.0	93.7	97.7	97.7	97.7
	5	0.0	74.6	98.0	98.4	98.4
	6	0.0	94.0	98.2	98.3	98.3
	7	0.0	70.1	102.4	103.0	102.9
	8	0.0	96.5	99.5	99.3	99.3
	9	0.0	86.8	99.6	99.7	99.7
	10	0.0	77.9	102.2	102.6	102.6
	11	0.0	93.3	100.6	100.6	100.6
	12	0.0	88.0	101.1	101.3	101.2
	Mean	0	87	100	100	100

20

Table 3 : Comparison of Dissolution Profiles by UV in 0.1 N HCl

Tablet B (50 mg) vs Imitrex Tablets 50 mg (GSK)

		Tablet	Time Points (Minutes)				
			0	5	10	15	20
5	100 mg	Tablet C	1	0.0	96.8	98.3	98.3
			2	0.0	97.3	98.4	98.1
			3	0.0	97.9	99.4	99.0
			4	0.0	97.2	98.5	98.3
			5	0.0	97.0	98.2	98.0
			6	0.0	97.4	98.1	97.8
			7	0.0	98.9	98.8	99.6
			8	0.0	100.1	101.1	100.6
			9	0.0	100.4	101.0	100.7
			10	0.0	100.4	101.6	101.8
			11	0.0	99.8	101.3	101.5
			12	0.0	99.6	100.9	101.3
		Mean	0	99	100	100	100
10	100 mg	Imitrex	1	0.0	94.0	100.0	100.1
			2	0.0	98.1	101.2	101.1
			3	0.0	97.6	99.5	99.6
			4	0.0	95.0	94.8	96.7
			5	0.0	95.4	96.8	96.8
			6	0.0	95.0	96.8	97.1
			7	0.0	93.1	98.3	99.1
			8	0.0	97.4	101.0	101.3
			9	0.0	99.9	101.8	101.8
			10	0.0	98.0	99.2	99.3
			11	0.0	95.9	98.0	98.2
			12	0.0	95.7	98.5	98.2
		Mean	0	96	99	99	99

20 **Table 4: Comparison of Dissolution Profiles by UV in 0.1 N HCl**

**Tablet C (100 mg) vs Imitrex Tablets 100 mg (GSK)**

As can be seen from Table 2, tablets of the invention containing 25mg of sumatriptan show rapid dissolution, with 99% (mean average) dissolution after 5 minutes and 100% dissolution after 10 minutes. This contrasts favourably with the  
5 Imitrex 25mg tablet, which, under the same conditions, shows only 65% mean average dissolution after 5 minutes, and 100% dissolution after 10 minutes.

Under the same conditions, tablets of the invention containing, respectively, 50mg and 100mg of sumatriptan show similarly impressive dissolution profiles (see Tables  
10 3 and 4).

The data in Tables 2-4 is represented graphically in Figures 2-4.

**15 Example 4**

A bio-study was carried out and showed the 100 mg tablets of Example 3 were bio-equivalent to the branded Glaxo product (Imitrex®). This study also showed that there was no report by patients of a unpleasant-taste when the tablets were taken.  
20 The study thus confirmed rapid release of active and adequate taste-masking by tablets of the invention.

Claims

1. A tablet, comprising:-
  - (i) a core containing sumatriptan, and
  - (ii) a mantle, free of sumatriptan.
2. A tablet according to Claim 1, wherein the weight ratio of mantle:core is equal to or less than 1.8:1.
- 10 3. A tablet according to Claim 1, wherein the weight ratio of mantle:core is equal to or less than 1.5:1.
4. A tablet according to any of Claims 1-3, wherein the core contains from 10-200 mg of sumatriptan.
- 15 5. A tablet according to any of Claims 1-4, wherein:-
  - (i) the core is composed of sumatriptan, a filler, a binder, a disintegrant and a lubricant, and
  - (ii) the mantle is composed of a filler, a binder, a disintegrant and a lubricant.
- 20 6. A tablet according to Claim 5, wherein the core and the mantle further comprise adsorbants and/or colorants.
- 25 7. A tablet according to Claim 6, wherein the core comprises, by weight:-

sumatriptan : 1-40%  
filler: 10-90%  
binder: 2-60%  
30 disintegrant: 1-60%

lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%,

5 and the mantle comprises, by weight:-

filler: 10-90%

binder: 2-60%

disintegrant: 1-60%

10 lubricant: 0.1-10%

adsorbants: 0-5%

colorants: 0-5%.

8. A tablet according to any previous Claim, wherein, apart from the sumatriptan

15 in the core, the core and the mantle are composed of substantially the same  
materials.

9. A tablet according to any previous Claim, wherein both the core and the  
mantle dissolve rapidly in the stomach.

20

10. A tablet according to Claim 9, wherein at least 90% of the tablet is dissolved  
after 10 minutes.

11. A tablet according to any of Claims 1-10 wherein the core and the mantle  
25 disintegrate over substantially the same time period.

12. A tablet according to Claim 11, wherein the mantle is at least 95 % dissolved  
and the core is at least 90 % dissolved after 10 minutes.

30 13. A method of producing a tablet according to any previous claim, comprising  
the steps of:-

- A) forming a core by:-
    - (i) placing a first amount of powder/granule in a press,
    - (ii) compressing said first amount of powder/granule to obtain a core, and
  - B) pressing a second amount of powder/granule around said core,
    - 5 thereby forming a mantle and obtaining the final tablet.
14. A method of producing a tablet according to Claim 13, comprising the steps of:-
- (A) forming a core by:-
    - (i) placing a first amount of powder/granule in a press,
    - (ii) compressing said first amount of powder/granule to obtain a core, and
  - 10 (B) forming a mantle around the core by:-
    - (i) placing a second amount of powder/granule in a press,
    - (ii) placing said core onto said second amount of powder/granule,
  - 15 (iii) placing a third amount of powder/granule on top of the core and the second amount of powder/granule, and
    - (iv) compressing (iii) so as to obtain the final tablet.
15. A method according to Claim 13 or 14, wherein the compression in Step A  
20 is carried out at a pressure of from 0.5-5 tons.
16. A method according to Claim 13 or 14, wherein the compression in Step B  
is carried out at a pressure of from 0.5-10 tons.
- 25 17. A method according to Claim 13 or 14, wherein the first amount of  
powder/granule comprises sumatriptan, a filler, a binder, a disintegrant and  
a lubricant.
- 30 18. A method according to Claim 13 or 14, wherein the first amount of  
powder/granule comprises, by weight:-

sumatriptan: 1-40%  
filler: 10-90%  
binder: 2-60%  
disintegrant: 1-60%  
5 lubricant: 0.1-10%  
adsorbants: 0-5%  
colorants: 0-5%.

19. A method according to Claim 13 or 14, wherein the second and/or third  
10 amounts of powder/granule comprise a filler, a binder, a disintegrant and a  
lubricant.
20. A method according to Claim 13 or 14, wherein the second and/or third  
amounts of powder/granule comprise, by weight:-
- 15 filler: 10-90%  
binder: 2-60%  
disintegrant: 1-60%  
lubricant: 0.1-10%  
adsorbants: 0-5%  
20 colorants: 0-5%.
21. A method according to Claim 13 or 14, wherein Step A results in a partially-compressed core, which core is then further compressed in Step B.

**COMPRESSION-COATED TABLETS  
AND THE MANUFACTURE THEREOF**


5

**ABSTRACT**

- 10 Tablets for the treatment of migraine comprise a core, containing the active agent sumatriptan or a pharmaceutically-acceptable salt or ester thereof, and a mantle, free of sumatriptan. Tablets are prepared by compressing mantle components, free of the active agent, around a partially-compressed, active-containing core.


15

**Figure 1**






**Figure 2**





**Figure 3**





**Figure 4**

